Key facts
- This page summarizes Decheng Capital China Life Sciences USD Fund III, L.P.'s Form 4 filing for BeyondSpring Inc. (BYSI).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 20 Oct 2025, 20:00.
Decheng Capital China Life Sciences USD Fund III, L.P. - 16 Oct 2025 Form 4 Insider Report for BeyondSpring Inc. (BYSI)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- BYSI
- Reported as of
- 16 Oct 2025
- Net transaction value
- -$227,675
- SEC form
- 4
- Accepted by SEC
- 20 Oct 2025, 20:00:02 UTC
- Prior SEC filing
- 15 Oct 2025
- Source filing
- View source filing
- Reporting owner signature
- Decheng Capital China Life Sciences USD Fund III, L.P., By Decheng Capital Management III (Cayman), LLC, its General Partner, By /s/ Xiangmin Cui, Manager
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Decheng Capital China Life Sciences USD Fund III, L.P. filed Form 4 for BeyondSpring Inc. (BYSI) on 20 Oct 2025.
Change
- Previous filing in this sequence was filed on 15 Oct 2025.
- Current net transaction value: -$227,675.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (7)
CIK 0001736814
Primary reporting owner
Decheng Capital China Life Sciences USD Fund III, L.P.
- Relationship
- 10%+ Owner
- Address
- C/O DECHENG CAPITAL, 3000 SAND HILL ROAD, BLDG. 2, SUITE 110, MENLO PARK
- Signature
- Decheng Capital China Life Sciences USD Fund III, L.P., By Decheng Capital Management III (Cayman), LLC, its General Partner, By /s/ Xiangmin Cui, Manager
- Signature date
- 20 Oct 2025
CIK 0001747821
Decheng Capital Management III (Cayman), LLC
- Relationship
- 10%+ Owner
- Address
- C/O DECHENG CAPITAL, 3000 SAND HILL ROAD, BLDG. 2, SUITE 110, MENLO PARK
- Signature
- Decheng Capital Management III (Cayman), LLC, By /s/Xiangmin Cui, Manager
- Signature date
- 20 Oct 2025
CIK 0001650291
Decheng Capital China Life Sciences USD Fund II, L.P.
- Relationship
- 10%+ Owner
- Address
- C/O DECHENG CAPITAL, 3000 SAND HILL ROAD, BLDG. 2, SUITE 110, MENLO PARK
- Signature
- Decheng Capital China Life Sciences USD Fund II, L.P., By Decheng Capital Management II (Cayman), LLC, its General Partner, By /s/ Xiangmin Cui, Manager
- Signature date
- 20 Oct 2025
CIK 0002089149
Decheng Capital Management II (Cayman), LLC
- Relationship
- 10%+ Owner
- Address
- C/O DECHENG CAPITAL, 3000 SAND HILL ROAD, BLDG. 2, SUITE 110, MENLO PARK
- Signature
- Decheng Capital Management II (Cayman), LLC, By /s/ Xiangmin Cui, Manager
- Signature date
- 20 Oct 2025
CIK 0001949026
Decheng Capital Global Healthcare Fund (Master), LP
- Relationship
- 10%+ Owner
- Address
- C/O DECHENG CAPITAL, 3000 SAND HILL ROAD, BLDG. 2, SUITE 110, MENLO PARK
- Signature
- Decheng Capital Global Healthcare Fund (Master), LP, By Decheng Capital Global Healthcare GP, LLC, its General Partner, By Decheng Capital LLC, its Manager, By /s/ Xiangmin Cui, Manager
- Signature date
- 20 Oct 2025
CIK 0001949027
Decheng Capital Global Healthcare GP, LLC
- Relationship
- 10%+ Owner
- Address
- C/O DECHENG CAPITAL, 3000 SAND HILL ROAD, BLDG. 2, SUITE 110, MENLO PARK
- Signature
- Decheng Capital Global Healthcare GP, LLC, By Decheng Capital LLC, its Manager, By /s/ Xiangmin Cui, Manager
- Signature date
- 20 Oct 2025
CIK 0001487815
Cui Xiangmin
- Relationship
- 10%+ Owner
- Address
- C/O DECHENG CAPITAL, 3000 SAND HILL ROAD, BLDG. 2, SUITE 110, MENLO PARK
- Signature
- /s/ Xiangmin Cui
- Signature date
- 20 Oct 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BYSI
transaction
Ordinary Shares
Sale
- Transaction value
- $147,573
- Shares
- -85,798
- Change %
- -5.2%
- Price
- $1.72
- Shares after
- 1,564,406
- Date
- 16 Oct 2025
- Ownership
- By Decheng Capital China Life Sciences USD Fund III, L.P.
- Footnotes
- F1, F2
BYSI
transaction
Ordinary Shares
Sale
- Transaction value
- $80,103
- Shares
- -45,513
- Change %
- -2.9%
- Price
- $1.76
- Shares after
- 1,518,893
- Date
- 17 Oct 2025
- Ownership
- By Decheng Capital China Life Sciences USD Fund III, L.P.
- Footnotes
- F2, F3
BYSI
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,617,409
- Date
- 16 Oct 2025
- Ownership
- By Decheng Capital China Life Sciences USD Fund II, L.P.
- Footnotes
- F4
BYSI
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 891,734
- Date
- 16 Oct 2025
- Ownership
- By Decheng Capital Global Healthcare Fund (Master), LP
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Decheng Capital China Life Sciences USD Fund III, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 5 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.795 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
Footnote F5
These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.